Biogen Inc. Files 8-K for Financial Results
Ticker: BIIB · Form: 8-K · Filed: 2026-04-06T06:31:37-04:00
Sentiment: neutral
Topics: financial-results, 8-k
Related Tickers: BIIB
TL;DR
Biogen dropped its Q1 2026 financials on 8-K today.
AI Summary
Biogen Inc. filed an 8-K report on April 6, 2026, to disclose its results of operations and financial condition. The filing includes various XBRL documents detailing financial information, such as schema, label, and presentation linkbases, along with an extracted XBRL instance document and an iXBRL 8-K.
Why It Matters
This filing provides crucial, up-to-date financial information for Biogen Inc., allowing investors and analysts to assess the company's performance and make informed decisions.
Risk Assessment
Risk Level: low — This is a routine filing of financial results, not indicating any unusual or significant risks.
Key Players & Entities
- BIOGEN INC. (company) — Filer of the 8-K report
- 0000875045 (company) — CIK number for Biogen Inc.
- 2026-04-06 (date) — Filing date and period of report
FAQ
What specific financial results are being reported in this 8-K filing?
The filing is an 8-K for 'Results of Operations and Financial Condition' filed on April 6, 2026, but the specific financial figures are not detailed in the provided text, only the type of report and filing date.
What is the CIK number for Biogen Inc.?
The CIK number for Biogen Inc. is 0000875045.
When was this 8-K filing accepted by the SEC?
The filing was accepted on 2026-04-06 at 06:31:37.
What is the business address of Biogen Inc.?
Biogen Inc.'s business address is 225 BINNEY STREET CAMBRIDGE MA 02142.
What SIC code is associated with Biogen Inc.?
The SIC code associated with Biogen Inc. is 2836, which pertains to Biological Products, (No Diagnostic Substances).
From the Filing
EDGAR Filing Documents for 0000875045-26-000039 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0000875045-26-000039 Filing Date 2026-04-06 Accepted 2026-04-06 06:31:37 Documents 13 Period of Report 2026-04-06 Items Item 2.02: Results of Operations and Financial Condition Interactive Data Document Format Files Seq Description Document Type Size 1 8-K biib-20260406.htm iXBRL 8-K 24871 5 biib-20260406_g1.jpg GRAPHIC 2811 Complete submission text file 0000875045-26-000039.txt 201808 Data Files Seq Description Document Type Size 2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT biib-20260406.xsd EX-101.SCH 2164 3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT biib-20260406_lab.xml EX-101.LAB 21885 4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT biib-20260406_pre.xml EX-101.PRE 24562 16 EXTRACTED XBRL INSTANCE DOCUMENT biib-20260406_htm.xml XML 2789 Mailing Address 225 BINNEY STREET CAMBRIDGE MA 02142 Business Address 225 BINNEY STREET CAMBRIDGE MA 02142 7814642000 BIOGEN INC. (Filer) CIK : 0000875045 (see all company filings) EIN. : 330112644 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 000-19311 | Film No.: 26839520 SIC : 2836 Biological Products, (No Diagnostic Substances) (CF Office: 03 Life Sciences)